Table 1 Craniofacial abnormalities of embryos exposed at different age stages to one of two concentrations of GDC-0449
Embryonic age | Pregnant females/n | Maternal lethality/n | Fetuses in total/n | Viable embryos/n | Stillbirths /n | Craniofacial anomalies /n | Ratio of affected fetuses /% |
|---|---|---|---|---|---|---|---|
100mg•kg−1 b.w. | |||||||
E8.5 | 3 | 1 | 36 | 30 | 6 | 0 | 0 |
E9.5 | 3 | 0 | 40 | 38 | 2 | 6 | 15.8 |
E10.5 | 3 | 0 | 39 | 39 | 0 | 9 | 23.1 |
E11.5 | 3 | 0 | 40 | 40 | 0 | 6 | 15 |
E12.5 | 3 | 0 | 42 | 42 | 0 | 10 | 23.8 |
150mg•kg−1 b.w. | |||||||
E8.5 | 5 | 2 | 39 | 24 | 15 | 0 | 0 |
E9.5 | 6 | 3 | 38 | 25 | 13 | 25 | 100 |
E10.5 | 3 | 0 | 41 | 34 | 7 | 34 | 100 |
E11.5 | 3 | 0 | 40 | 38 | 2 | 16 | 42.1 |
E12.5 | 3 | 0 | 41 | 41 | 0 | 20 | 48.8 |
